

Who supplies Africa's biggest malaria markets, India or China?

In the 12 African countries that carried 75.7 per cent of the WHO African Region's estimated malaria cases in 2024, plus Kenya: who supplies the antimalarial medicines (HS 300460), India or China, and is that changing?

PUBLISHED	8 October 2026, solgravitas.com/insights/india-or-china-africas-malaria-medicines
PERIOD	Calendar years 2021 to 2025
RECORDS USED	TRADESTAT MEIDB (India's export records); UN Comtrade (China's export records and each importer's own records); The Global Fund Price & Quality Reporting and List of Malaria Pharmaceutical Products v132; WHO World Malaria Report 2025
RETRIEVED	8 October 2026, every figure
EVIDENCE LOG	solgravitas.com/sol-gravititas-antimalarial-study-evidence-log.csv , 245 entries
DATA REPORT	Version 1, 11 October 2026. Same figures as the published study, presented as tables.

Findings, as plain statements.

Three separate records were checked against each other: what the exporting countries say they shipped, what the importing countries say they received, and what the Global Fund bought and who made it. Where they agree, the finding is stated. Where they disagree, both are shown.

WHO THIS REPORT IS FOR

A maker or exporter of antimalarial medicines in India or China deciding which African markets to pursue and which products to lead with; a procurement or supply-chain officer who needs to know who actually makes what the Global Fund buys; and anyone who has been quoted a share of this market and wants to see the record it rests on. The tables give the figures. The method and limits pages say how far they can be trusted.

- 01** By the exporters' own records, India shipped \$121.0 million of HS 300460 to the 12 countries in 2021 and China \$62.6 million. In 2025 the two were level: \$89.6 million and \$89.3 million.
- 02** In 2024 China shipped more than India for the first time in the period, \$105.4 million against \$98.6 million. China sent more than India to one of the 12 countries in 2021 and to six in 2025.
- 03** By weight India still led in 2025, with 54.5 per cent of the kilograms shipped.
- 04** The 12 markets took 63.6 per cent of China's exports of these medicines in 2025 and 48.4 per cent of India's. India's exports to all countries fell from \$223.7 million to \$185.1 million over the period; China's rose from \$113.9 million to \$140.5 million.
- 05** For the eight countries with import records every year from 2022 to 2025, the importers' own records show India's share of India-plus-China supply falling from 71.5 per cent to 64.2 per cent. The exporters' records for the same eight show a steeper fall, 73.8 to 49.4 per cent. The direction agrees; the size does not.
- 06** Across 50 country-years with import records, the two sides agree on which supplier was larger in 40.
- 07** Global Fund purchases for the 13 countries, deliveries 2021 to 2025, came to \$442.7 million. 45.6 per cent was made in China, all of it by one maker, Guilin Pharmaceutical (Fosun Pharma). Between 31.2 and 44.4 per cent was made in India.
- 08** China made 94.3 per cent of the SPAQ co-blister, 71.3 per cent of injectable artesunate and all of the dihydroartemisinin-piperaquine. Factories in India made at least 50.3 per cent of artemether-lumefantrine, the largest product at \$171.9 million; no China-only maker supplied it.
- 09** China leads where purchases are mostly SPAQ and artesunate (Niger, Mali, Nigeria). India leads where those two products are a small part of purchases (Ethiopia, Côte d'Ivoire, Kenya). DR Congo and Madagascar are exceptions on each side.
- 10** India reports \$13.9 to \$24.9 million a year of exports to Kenya; Kenya records far less from India and re-exports almost none. The published records do not show where the difference goes.

The countries, and the exporters' records.

HS 300460 covers medicaments containing artemisinin or its derivatives, the main class of malaria treatment. The exporters' records are each country's own account of what it shipped.

The countries in this study

COUNTRY	RANK IN THE WHO AFRICAN REGION	ESTIMATED MALARIA CASES, 2024
Nigeria	1	68,466,353
DR Congo	2	35,175,261
Uganda	3	13,215,579
Ethiopia	4	12,436,942
Mozambique	5	10,219,719
Angola	6	9,808,643
Tanzania	7	9,373,891
Côte d'Ivoire	8	8,556,747
Mali	9	8,474,969
Burkina Faso	10	8,324,231
Niger	11	8,248,768
Madagascar	12	8,165,311
Kenya	20	4,185,536
WHO African Region, all countries		264,778,661
Share of the Region's cases in the 12 countries (Kenya excluded)		75.7 %

Kenya, ranked 20th, is included because it is a frequent destination in India's export records. Source: WHO, World Malaria Report 2025, Annex 4H. Retrieved 8 October 2026.


Exporters' records: exports of HS 300460 to the 12 countries combined

YEAR	INDIA, US\$ M	CHINA, US\$ M	INDIA SHARE, VALUE %	INDIA SHARE, WEIGHT %	INDIA, KG	CHINA, KG	COUNTRIES WHERE CHINA SENT MORE
2021	121.0	62.6	65.9	59.1	4,627,842	3,200,287	1
2022	108.6	55.0	66.4	65.2	4,264,573	2,277,224	4
2023	95.4	55.0	63.4	59.3	4,083,573	2,799,265	4
2024	98.6	105.4	48.3	50.3	4,648,961	4,599,470	5
2025	89.6	89.3	50.1	54.5	4,591,583	3,836,505	6

Shares are India ÷ (India + China). Sources: TRADESTAT MEIDB, Department of Commerce, Government of India (India's exports, calendar years); UN Comtrade, exports reported by China. Retrieved 8 October 2026.

India's lead narrowed to level.

Antimalarial medicines (HS 300460) shipped to the 12 countries, US \$ million, each exporter's own records



Sources: TRADESTAT MEIDB, Department of Commerce, Government of India; UN Comtrade, exports reported by China. Retrieved 8 October 2026.

India's and China's exports of HS 300460 to the 12 countries combined, calendar years, each exporter's own records. Sources: TRADESTAT MEIDB, Department of Commerce, Government of India (India's exports, calendar years); UN Comtrade, exports reported by China. Retrieved 8 October 2026.

India's record of exports to each country, US\$ million

COUNTRY	2021	2022	2023	2024	2025
Nigeria	55.07	44.31	50.90	32.83	34.89
DR Congo	13.87	8.15	9.41	8.72	8.06
Uganda	11.53	10.50	7.76	2.94	3.47
Ethiopia	1.47	2.51	2.69	8.73	8.95
Mozambique	6.77	4.01	6.59	7.41	4.50
Angola	5.07	6.27	3.39	7.13	4.50
Tanzania	12.90	17.10	7.57	13.63	10.32
Côte d'Ivoire	3.50	6.74	4.11	4.25	6.91
Mali	1.72	2.16	0.42	1.64	1.14
Burkina Faso	5.23	5.62	0.66	8.72	5.96
Niger	1.92	0.08	0.69	1.34	0.01
Madagascar	1.97	1.17	1.24	1.26	0.90
Kenya	13.94	24.92	21.38	22.07	20.69

Source: TRADESTAT MEIDB, Department of Commerce, Government of India, HS 300460, calendar years. Retrieved 8 October 2026.

China's record of exports to each country, US\$ million

COUNTRY	2021	2022	2023	2024	2025
Nigeria	29.80	13.86	21.76	46.35	38.94
DR Congo	9.68	12.03	4.71	12.15	10.78
Uganda	2.20	5.83	6.49	9.19	7.63
Ethiopia	0.62	0.95	0.52	5.86	2.09
Mozambique	1.16	3.80	0.38	2.27	1.56
Angola	3.98	2.05	3.25	2.55	3.26
Tanzania	5.13	3.10	6.32	4.49	7.11
Côte d'Ivoire	1.46	2.30	1.42	0.48	2.10
Mali	1.24	3.34	2.00	6.24	3.04
Burkina Faso	4.08	6.66	3.90	4.86	6.45
Niger	2.41	0.43	2.18	10.23	6.20
Madagascar	0.81	0.63	2.07	0.70	0.18
Kenya	3.57	3.28	1.46	2.46	2.28

Source: UN Comtrade, exports reported by China, HS 300460, calendar years. Retrieved 8 October 2026.

India's share of India + China, by the exporters' records, value %

COUNTRY	2021	2022	2023	2024	2025
Nigeria	64.9	76.2	70.1	41.5	47.3
DR Congo	58.9	40.4	66.7	41.8	42.8
Uganda	84.0	64.3	54.5	24.2	31.3
Ethiopia	70.3	72.5	83.7	59.8	81.1
Mozambique	85.3	51.4	94.5	76.5	74.3
Angola	56.0	75.3	51.1	73.6	58.0
Tanzania	71.5	84.7	54.5	75.2	59.2
Côte d'Ivoire	70.5	74.5	74.3	89.9	76.7
Mali	58.1	39.2	17.3	20.8	27.3
Burkina Faso	56.2	45.8	14.5	64.2	48.0
Niger	44.3	15.6	24.0	11.6	0.2
Madagascar	70.8	64.9	37.4	64.2	83.1
Kenya	79.6	88.4	93.6	90.0	90.1

Sources: TRADESTAT MEIDB, Department of Commerce, Government of India (India's exports, calendar years); UN Comtrade, exports reported by China. Retrieved 8 October 2026.

Each exporter's total exports of HS 300460 to all countries, and the share going to the 12

YEAR	INDIA, ALL COUNTRIES, US\$ M	SHARE TO THE 12, %	CHINA, ALL COUNTRIES, US\$ M	SHARE TO THE 12, %	INDIA TO FRANCE, US\$ M
2021	223.7	54.1	113.9	54.9	34.4
2022	214.9	50.5	92.8	59.2	30.9
2023	196.6	48.5	104.4	52.7	24.6
2024	199.7	49.4	156.0	67.5	33.0
2025	185.1	48.4	140.5	63.6	34.5

India's exports to France are shown because routing through France is one possible reason for gaps between importers' and exporters' records; this was not tested. Sources: TRADESTAT MEIDB, Department of Commerce, Government of India (India's exports, calendar years); UN Comtrade, exports reported by China. Retrieved 8 October 2026.

Export value per kilogram to the 12 countries, US\$/kg

YEAR	INDIA	CHINA
2021	26.15	19.56
2022	25.47	24.15
2023	23.37	19.65
2024	21.21	22.91
2025	19.52	23.29

Values per kilogram are not prices: weights mix tablets, vials and packaging. Sources: TRADESTAT MEIDB, Department of Commerce, Government of India (India's exports, calendar years); UN Comtrade, exports reported by China. Retrieved 8 October 2026.

The importers' records.

An exporter records where goods are sent. An importer records where goods were made. The two records are kept by different governments and can be set against each other.


Importers' records: the eight countries with import records in every year 2022 to 2025

YEAR	IMPORTS FROM INDIA, US\$ M	IMPORTS FROM CHINA, US\$ M	INDIA SHARE, IMPORTERS' RECORDS %	INDIA SHARE, EXPORTERS' RECORDS %
2022	47.33	18.85	71.5	73.8
2023	44.39	17.95	71.2	65.2
2024	56.26	41.12	57.8	48.1
2025	61.60	34.34	64.2	49.4

The eight: Nigeria, Uganda, Mozambique, Angola, Tanzania, Côte d'Ivoire, Niger and Madagascar. Shares are India ÷ (India + China). Sources: UN Comtrade, imports reported by each country; TRADESTAT MEIDB; UN Comtrade, exports reported by China. Retrieved 8 October 2026.

Same direction, different size.

India's share of India + China supply, the eight countries with import records every year from 2022 to 2025, per cent



Countries: Nigeria, Uganda, Mozambique, Angola, Tanzania, Côte d'Ivoire, Niger, Madagascar.

Sources: UN Comtrade, imports reported by each country; TRADESTAT MEIDB, Department of Commerce, Government of India; UN Comtrade, exports reported by China. Retrieved 8 October 2026.

India's share of India + China supply to the same eight countries, by the importers' records and by the exporters' records. Sources: UN Comtrade, imports reported by each country; TRADESTAT MEIDB; UN Comtrade, exports reported by China. Retrieved 8 October 2026.

Each country's recorded imports of HS 300460 from all sources, US\$ million

COUNTRY	2021	2022	2023	2024	2025
Nigeria	no record	20.19	20.71	39.24	42.55
DR Congo	no record	no record	no record	13.34	no record
Uganda	2.39	0.70	8.77	5.53	5.26
Ethiopia	1.65	0.91	1.01	no record	no record
Mozambique	2.25	3.67	1.58	5.72	0.25
Angola	16.31	24.55	17.93	18.47	19.76
Tanzania	10.54	5.26	7.56	7.79	4.23
Côte d'Ivoire	21.89	25.07	24.66	27.52	35.63
Mali	6.37	6.38	5.99	no record	no record
Burkina Faso	8.52	21.59	8.77	19.84	no record
Niger	12.10	8.32	6.57	18.17	11.99
Madagascar	2.86	3.18	2.90	2.44	2.04
Kenya	1.26	3.37	3.49	4.19	5.94

Source: UN Comtrade, imports reported by each country, HS 300460. Retrieved 8 October 2026.

India's share of India + China, by each importer's own records, value %

COUNTRY	2021	2022	2023	2024	2025
Nigeria	no record	90.2	85.8	49.7	57.1
DR Congo	no record	no record	no record	49.1	no record
Uganda	90.4	70.0	97.3	40.0	54.8
Ethiopia	64.8	39.1	12.1	no record	no record
Mozambique	100.0	91.8	38.6	98.7	62.4
Angola	70.1	81.8	64.0	78.3	74.6
Tanzania	66.8	73.8	55.4	52.6	73.1
Côte d'Ivoire	76.4	64.2	74.1	75.7	78.1
Mali	77.8	41.9	55.0	no record	no record
Burkina Faso	19.4	61.8	40.9	48.3	no record
Niger	38.2	21.0	59.2	29.8	30.0
Madagascar	53.0	54.2	10.8	75.2	61.2
Kenya	39.8	20.2	17.8	62.3	73.2

"No record" means the country did not report imports of HS 300460 to UN Comtrade for that year on the retrieval date. Source: UN Comtrade, imports reported by each country, HS 300460. Retrieved 8 October 2026.

The ten country-years where the two records disagree on which supplier was larger

COUNTRY	YEAR	INDIA SHARE, IMPORTER'S RECORD %	INDIA SHARE, EXPORTERS' RECORDS %	LARGER SUPPLIER, IMPORTER	LARGER SUPPLIER, EXPORTERS
Nigeria	2025	57.1	47.3	India	China
Uganda	2025	54.8	31.3	India	China
Ethiopia	2022	39.1	72.5	China	India
Ethiopia	2023	12.1	83.7	China	India
Mozambique	2023	38.6	94.5	China	India
Mali	2023	55.0	17.3	India	China
Burkina Faso	2021	19.4	56.2	China	India
Burkina Faso	2022	61.8	45.8	India	China
Burkina Faso	2024	48.3	64.2	China	India
Niger	2023	59.2	24.0	India	China

Of 50 country-years with import records (out of 60 possible), the two sides agree on the larger supplier in 40. Sources: UN Comtrade, imports reported by each country; TRADESTAT MEIDB; UN Comtrade, exports reported by China. Retrieved 8 October 2026.

Kenya: the two records do not meet

YEAR	INDIA'S RECORD OF EXPORTS TO KENYA, US\$ M	KENYA'S RECORD OF IMPORTS FROM INDIA, US\$ M	KENYA'S RE-EXPORTS OF HS 300460 TO ALL COUNTRIES, US\$ M
2021	13.94	0.48	0.01
2022	24.92	0.61	0.20
2023	21.38	0.60	0.03
2024	22.07	2.51	0.09
2025	20.69	4.17	0.18

Sources: TRADESTAT MEIDB, Department of Commerce, Government of India; UN Comtrade, Kenya's own reports. Retrieved 8 October 2026.

Global Fund purchases: who made what.

Global Fund records name the maker of each purchase they list. Each maker was matched to its factory country using the Global Fund's own list of approved manufacturing sites. These records cover purchases paid for with Global Fund grants only.


Global Fund purchases by product and by the country of the maker's listed factories, deliveries 2021 to 2025, US\$ million

PRODUCT	TOTAL	MADE IN INDIA	INDIA OR ANOTHER LISTED SITE	MADE IN CHINA	ELSEWHERE	CHINA %	INDIA, FIRM %	INDIA, UPPER %
Artemether-lumefantrine	171.93	86.56	58.54	0.00	26.84	0.0	50.3	84.4
Artesunate (98.6% injectable)	106.93	31.83	0.00	75.11	0.00	70.2	29.8	29.8
SPAQ co-blister	94.33	5.37	0.00	88.96	0.00	94.3	5.7	5.7
Artesunate-amodiaquine	26.73	14.33	0.00	5.73	6.66	21.5	53.6	53.6
Dihydroartemisinin-piperaquine	19.82	0.00	0.00	19.82	0.00	100.0	0.0	0.0
Sulfadoxine-pyrimethamine	16.64	0.00	0.00	12.35	4.29	74.2	0.0	0.0
Artesunate-pyronaridine	5.44	0.00	0.00	0.00	5.44	0.0	0.0	0.0
Primaquine	0.83	0.00	0.00	0.00	0.83	0.0	0.5	0.5
All products	442.66	138.09	58.54	201.98	44.06	45.6	31.2	44.4

"India or another listed site" covers makers whose product lists factories both in India and in Kenya, Uganda or Zambia, so the country of manufacture for a given purchase is not identified. "Elsewhere" includes a maker listing factories in China, the USA and Türkiye. All China-site purchases are from one maker, Guilin Pharmaceutical (Fosun Pharma). Sources: The Global Fund, Price & Quality Reporting (PQR), transaction summary, deliveries 2021 to 2025; The Global Fund, List of Malaria Pharmaceutical Products, version 132, 30 September 2026, for each maker's listed factory sites. Retrieved 8 October 2026.

China and India mostly make different medicines.

Global Fund-financed purchases for the 13 countries, by where the medicine was made, deliveries 2021 to 2025



Sources: The Global Fund, Price & Quality Reporting; Global Fund List of Malaria Pharmaceutical Products, version 132. Retrieved 8 October 2026.

Global Fund-financed purchases for the 13 countries, deliveries 2021 to 2025, by product and by the country of the maker's listed sites. Sources: The Global Fund, Price & Quality Reporting (PQR), transaction summary, deliveries 2021 to 2025; The Global Fund, List of Malaria Pharmaceutical Products, version 132, 30 September 2026, for each maker's listed factory sites. Retrieved 8 October 2026.

Global Fund purchases by delivery year, 13 countries

DELIVERY YEAR	PURCHASES, US\$ M	MADE IN CHINA %	MADE IN INDIA, FIRM %	MADE IN INDIA, UPPER BOUND %
2021	99.53	39.9	35.3	49.0
2022	110.01	45.2	32.5	47.5
2023	73.24	51.5	25.5	39.8
2024	90.01	52.2	26.3	38.1
2025	69.86	39.9	35.5	46.0
2021 to 2025	442.66	45.6	31.2	44.4

The upper bound for India adds the purchases whose makers list sites in India and one other country. 2025 entries may still be incomplete on the retrieval date. Sources: The Global Fund, Price & Quality Reporting (PQR), transaction summary, deliveries 2021 to 2025; The Global Fund, List of Malaria Pharmaceutical Products, version 132, 30 September 2026, for each maker's listed factory sites. Retrieved 8 October 2026.


Global Fund purchases by country and by the country of the maker's listed factories, deliveries 2021 to 2025

COUNTRY	PURCHASES, US\$ M	MADE IN CHINA %	MADE IN INDIA %	INDIA OR ANOTHER LISTED SITE %	ELSEWHERE %	SPAQ AND ARTESUNATE AS SHARE OF SPEND %
Nigeria	100.18	68.7	21.4	9.9	0.0	68.6
DR Congo	70.26	45.5	26.0	9.7	18.9	33.5
Uganda	86.59	23.4	34.8	26.1	15.7	26.8
Ethiopia	6.84	0.0	88.0	0.0	12.0	0.0
Mozambique	22.03	22.3	43.2	20.3	14.2	10.9
Angola	7.20	16.3	65.4	11.5	6.8	31.2
Tanzania	33.17	30.3	40.4	21.1	8.2	40.3
Côte d'Ivoire	7.49	2.5	66.7	5.2	25.6	7.8
Mali	10.69	73.7	13.8	6.3	6.3	73.7
Burkina Faso	53.27	48.1	34.2	6.3	11.3	60.3
Niger	29.82	78.7	13.5	3.2	4.6	80.0
Madagascar	9.60	79.5	19.5	0.0	1.0	28.8
Kenya	5.53	0.0	71.8	28.2	0.0	11.0

The last column shows how much of each country's purchases were the two products China mostly makes, the SPAQ co-blister and injectable artesunate. Sources: The Global Fund, Price & Quality Reporting (PQR), transaction summary, deliveries 2021 to 2025; The Global Fund, List of Malaria Pharmaceutical Products, version 132, 30 September 2026, for each maker's listed factory sites. Retrieved 8 October 2026.

Where China leads, and where India does.

Global Fund-financed purchases by where the medicine was made, deliveries 2021 to 2025, per cent



Sources: The Global Fund, Price & Quality Reporting; Global Fund List of Malaria Pharmaceutical Products, version 132. Retrieved 8 October 2026.

Global Fund-financed purchases in each country, deliveries 2021 to 2025, by the country of the maker's listed sites. Sources: The Global Fund, Price & Quality Reporting (PQR), transaction summary, deliveries 2021 to 2025; The Global Fund, List of Malaria Pharmaceutical Products, version 132, 30 September 2026, for each maker's listed factory sites. Retrieved 8 October 2026.

Country summary: India's share of India + China on each record, and who made the Global Fund purchases

COUNTRY	WHO RANK	EXPORTERS' RECORDS 2021, INDIA %	EXPORTERS' RECORDS 2025, INDIA %	IMPORTER'S OWN RECORD, LATEST YEAR, INDIA %	GLOBAL FUND: MADE IN CHINA %	GLOBAL FUND: MADE IN INDIA %
Nigeria	1	64.9	47.3	57.1 (2025)	68.7	21.4
DR Congo	2	58.9	42.8	49.1 (2024)	45.5	26.0
Uganda	3	84.0	31.3	54.8 (2025)	23.4	34.8
Ethiopia	4	70.3	81.1	12.1 (2023)	0.0	88.0
Mozambique	5	85.3	74.3	62.4 (2025)	22.3	43.2
Angola	6	56.0	58.0	74.6 (2025)	16.3	65.4
Tanzania	7	71.5	59.2	73.1 (2025)	30.3	40.4
Côte d'Ivoire	8	70.5	76.7	78.1 (2025)	2.5	66.7
Mali	9	58.1	27.3	55.0 (2023)	73.7	13.8
Burkina Faso	10	56.2	48.0	48.3 (2024)	48.1	34.2
Niger	11	44.3	0.2	30.0 (2025)	78.7	13.5
Madagascar	12	70.8	83.1	61.2 (2025)	79.5	19.5
Kenya	20	79.6	90.1	73.2 (2025)	0.0	71.8

Sources: WHO World Malaria Report 2025, Annex 4H; TRADESTAT MEIDB; UN Comtrade; The Global Fund. Retrieved 8 October 2026.

How this was checked.

Three records were used. India's export records come from TRADESTAT MEIDB, the Department of Commerce's database, by partner country and calendar year. China's export records and each African country's import records come from UN Comtrade, as reported by each government. Global Fund purchases come from the Fund's Price & Quality Reporting transaction summary, filtered to antimalarial medicines delivered to the 13 countries between 2021 and 2025.

Each Global Fund purchase names a maker. The maker was matched to a factory country using the Global Fund's List of Malaria Pharmaceutical Products, version 132, which lists every approved manufacturing site. Where a maker lists sites in India and in one other country for the same product, the purchase is shown as "India or another listed site" rather than assigned to either.

Shares are always $\text{India} \div (\text{India} + \text{China})$ unless stated. Import values usually include freight and insurance; export values usually do not, so the two records are compared on direction and share, not on absolute value.

Every figure in the study was recomputed a second time, independently, from the same downloaded files: 112 figures, all matching. The maker-to-country mapping was rebuilt from the Global Fund list without reference to the first version. Ten figures were then read again by hand against the live sources on 8 October 2026; all ten matched.

Where the records disagree, both are shown and no cause is offered. Where no official source explains a movement, the study says so.

The Research Standard applied to every figure

01 Named, checkable source Every figure comes from a source that can be named and opened: an official database, a company filing, or a record Sol Gravitass retrieved itself.	02 Checked against a second record Each finding is checked against a second, separate source. Where the two disagree, the gap is stated or the figure is dropped.
03 Method and date stated The query path and the retrieval date are recorded for every figure, so anyone can repeat the retrieval.	04 Limits stated What the records cannot show is written down. If any gate fails, the finding does not ship.

EVIDENCE LOG

Every figure in the study and in this report is listed in the evidence log with its source, the query path or selection used, the retrieval date, the method, and the result of the independent recompute and the hand re-key check. The log is free at solgravitas.com/sol-gravitas-antimalarial-study-evidence-log.csv.

What these records cannot show.

Some import records are missing. Nigeria 2021; DR Congo every year except 2024; Ethiopia and Mali after 2023; Burkina Faso 2025.

Global Fund records cover only Global Fund purchases. Other donors, government budgets and private pharmacies are not included. The yearly China share in these records moves up and down (39.9, 45.2, 51.5, 52.2 and 39.9 per cent for 2021 to 2025) and shows no steady trend. 2025 entries may still be incomplete.

Some Global Fund rows repeat. \$6.51 million of rows repeat another row exactly. They were kept as reported. Removing them leaves the China share at 45.6 per cent and moves the firm India share to 31.4 per cent.

One maker lists factories in three countries. Novartis artemether-lumefantrine lists factories in China, the USA and Türkiye and is counted as made elsewhere. Counting it as Chinese would raise the China share to 48.4 per cent.

Weights are not treatments. Weights mix tablets, vials and packaging, so a share by weight is not a count of treatments. Values per kilogram are not prices.

Different values. Import values usually include freight and insurance; export values usually do not.

TRADESTAT is not the official record. TRADESTAT states that its data have no legal sanctity and are for general reference only, and points to DGCI&S, Kolkata publications for official reference.

The Global Fund figures have no second public record. No other public source records these purchases by maker, so they could not be checked against a second record. They were recomputed separately from the same files, the mapping was rebuilt independently, and two entries were read again by hand.

No causes are stated. Routing through France is a possibility the records allow, not a finding. This report is general information, not business, investment, legal or medical advice.

Sol Gravitass will publish any correction provided by the Department of Commerce, the UN Statistics Division, the Global Fund, the World Health Organization or any other party, in full and without editing. Corrections and queries: info@solgravitas.com

This report answers one question for everyone. *A commissioned one answers yours.*

Everything in this document was built from public records and is published free. The same method, applied to one firm's own markets, products and competitors, produces a brief that is scoped to that firm's decision and kept private to it.

SECTOR BRIEF

One sector, one question, a written answer with the data tables, the evidence log and a one-page owner summary in English, Hindi or Gujarati. Pricing on request.

CUSTOM RESEARCH AND MONITORING

Several markets, interviews or surveys, or the same question re-run every quarter as the records update. Scope, method, deliverables and cost agreed in writing before work starts.

Sol Gravitas™ is a market research and intelligence firm registered in India. Registration numbers are provided on request and confirmed in every proposal and invoice.